Aseda Sciences — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Aseda Sciences operates at the intersection of AI, phenotypic screening, and cheminformatics, offering a SaaS platform (3 RnD®) to de-risk chemical development. The platform analyzes compounds against a curated database of over 3,000 historical compounds with known safety profiles to predict toxicity, guiding safer compound design from hit-to-lead stages. The company serves a broad range of chemical industries, including pharmaceuticals, agrochemicals, and cosmetics, with the aim of improving human and environmental safety while accelerating R&D timelines. Its approach aligns with global sustainability goals and the industry-wide push to reduce animal testing.

NeuroscienceRare Disease

Technology Platform

Cloud-based AI platform (3 RnD®) that integrates high-content phenotypic screening in human cells with machine learning to generate biological fingerprints for compounds. These fingerprints are compared to a database of over 3,000 historical compounds to predict toxicity risk and guide safer chemical design.

Opportunities

Growing regulatory and societal pressure to reduce animal testing (3Rs) creates a strong mandate for alternative methods.

The high cost of late-stage failure in chemical and drug development drives demand for earlier, more predictive safety tools across pharmaceuticals, agrochemicals, and consumer goods.

Risk Factors

Key risks include the need for continuous validation of the platform's predictive accuracy against real-world outcomes and achieving regulatory acceptance.

The company also faces significant competition from other AI-driven toxicology platforms and must navigate long sales cycles in traditionally conservative industries.

Competitive Landscape

Aseda operates in the competitive *in vitro* and *in silico* predictive toxicology space, competing with specialized AI-biotech companies (e.g., Recursion, Exscientia in broader drug discovery), established toxicology software providers, and large contract research organizations (CROs) that are adding computational capabilities. Its differentiation lies in the specific integration of its own phenotypic screening data with its AI and visualization tools.

More companies in AI / Machine Learning →More companies in Switzerland →